Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: CAB LA, RPV LA, RPV, DTG; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 25
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more

Conditions: HIV Infection
Interventions: dolutegravir, lamivudine, Continue current antiretroviral regimen; Drug
Lead sponsor: Babafemi Taiwo; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 7
States / cities: San Diego, California • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: HIV Infections
Interventions: DTG 50 mg, RPV 25 mg, CAR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 13
States / cities: Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: ABC/DTG/3TC FDC, Ongoing cART regimen; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 87
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more

Conditions: HIV-1
Interventions: F/TAF, 3rd ARV agent, Boosted PIs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more

Conditions: HIV-1
Interventions: D/C/F/TAF FDC, TAF/FTC FDC, INI Based Regimen; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 34
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 28 more

Conditions: HIV Infection, HIV
Interventions: Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: EVG, Background regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee

Conditions: HIV Infections
Interventions: Kaletra + Current Dual NRTI Backbone, Current Regimen; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more

Conditions: HIV-1-infection
Interventions: Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 40
States / cities: Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more

Conditions: Kaposi's Sarcoma
Interventions: Maraviroc; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: B/FTC/TAF, Current ART; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more

Conditions: HIV Infection, Hyperlipidemia
Interventions: Atazanavir, current antiretroviral regimen; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more

Conditions: HIV Infections
Interventions: Aldesleukin, HAART; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
Interventions: Dolutegravir 50 MG, Antiretroviral/Anti HIV; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: HIV Infections
Interventions: DTG/3TC FDC, CAR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 16
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more

Conditions: HIV Infections
Interventions: DTG 50 mg, RPV 25 mg, CAR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 13
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Los Angeles, California • Sacramento, California • Ft. Pierce, Florida + 16 more

Conditions: HIV-1-infection, Pregnancy, Postpartum
Interventions: CAB LA 600mg, RPV LA 900mg, CAB LA 400mg, RPV LA 600mg; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: La Jolla, California • Los Angeles, California • Baltimore, Maryland + 1 more

Conditions: HIV
Interventions: atazanavir/raltegravir, atazanavir/tenofovir/emtricitabine; Drug
Lead sponsor: Community Research Initiative of New England; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more

Conditions: HIV Infections
Interventions: Dolutegravir 50 mg twice daily, Dolutegravir placebo twice daily; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 25
States / cities: Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 21 more

Conditions: HIV Infections
Interventions: Elvucitabine; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Orlando, Florida • Pensacola, Florida • Newark, New Jersey + 2 more

Search by objective public record fields.

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

Baricitinib Curative Repression of HIV-1

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

(mo)BETTA Trial in Transwomen for Optimization of ART

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment